

**IN THE CLAIMS:**

PLEASE AMEND THE CLAIMS AS FOLLOWS:

Please cancel claims 15, 16, 30, 31, 60 and 61;

Please amend claims 1, 17 and 47 as follows:

1. (Presently amended) A method for diminishing, inhibiting or eliminating addiction-related behavior of a mammal, wherein said method comprises administering to said mammal an effective amount of a composition consisting essentially of topiramate or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof, and wherein the addiction-related behavior is associated with cocaine or nicotine addiction.

2. (Original) A method according to claim1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an aversive response to said composition.

3. (Original) A method according to claim1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an appetitive response to said composition.

4. (Original) A method according to claim1, wherein said addiction-related behavior is diminished, inhibited or eliminated without an alteration in locomotor function of said mammal.

5. (Cancelled)

5/6. (Original) A method according to claim 1, wherein said addiction related

behavior is conditioned place preference.

7-8. (Cancelled)

6 ~~9~~. (Original) A method according to claim 1, wherein said composition comprises topiramate administered in an amount of about 25mg to about 1g/day.

10-12. (Cancelled)

7 ~~13~~. (Original) A method according to claim 1, wherein said composition is not addictive to said mammal.

8 ~~14~~. (Original) A method according to claim 1, wherein said mammal is a primate.

15-16. (Cancelled)

9 ~~17~~. (Presently Amended) A method for diminishing, inhibiting or eliminating cravings associated with addiction to ~~drugs of abuse~~ cocaine or nicotine in a mammal, wherein said method comprises administering to said mammal an effective amount of a composition consisting essentially of topiramate or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.

10 ~~18~~. (Original) A method according to claim <sup>9</sup>~~17~~, wherein said cravings are diminished, inhibited or eliminated without an aversive response to said composition.

11 ~~19~~. (Original) A method according to claim <sup>9</sup>~~17~~, wherein said cravings are diminished, inhibited or eliminated without an appetitive response to said composition.

12 ~~20~~. (Original) A method according to claim <sup>9</sup>~~17~~, wherein said cravings are diminished, inhibited or eliminated without an alteration in locomotor function of said mammal

21-23. (Cancelled)

13 ~~24~~. (Original) A method according to claim ~~17~~<sup>9</sup>, wherein said composition comprises topiramate administered in an amount of about 25mg to about 1g/day.

25-27. (Cancelled)

14 ~~28~~. (Original) A method according to claim ~~17~~<sup>9</sup>, wherein said mammal is a primate.

15 ~~29~~. (Original) A method according to claim ~~17~~<sup>9</sup>, wherein said composition is not addictive to said mammal.

30-46. (Cancelled)

16 ~~47~~. (Presently Amended) A method for diminishing, inhibiting or eliminating dependency characteristics associated with addiction to ~~drugs of abuse~~ cocaine or nicotine in a mammal, wherein said method comprises administering to said mammal an effective amount of a composition consisting essentially of topiramate, or a pharmaceutically acceptable salt thereof, or an enantiomer or racemic mixture thereof.

17 ~~48~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said dependency characteristics are diminished, inhibited or eliminated without an aversive response to said composition.

18 ~~49~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said dependency characteristics are diminished, inhibited or eliminated without an appetitive response to said composition.

19 ~~50~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said dependency

characteristics are diminished, inhibited or eliminated without an alteration of locomotor function in said mammal.

51-53. (Cancelled)

20 ~~54~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said composition comprises topiramate administered in an amount of about 25mg to about 1g/day.

55-57 (Cancelled)

21 ~~58~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said mammal is a primate.

22 ~~59~~. (Original) A method according to claim ~~47~~<sup>16</sup>, wherein said composition is not addictive to said mammal.

60-96. (Cancelled)